The approval marks a significant milestone for the American pharmaceutical company in the field of UC
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Application based on results from the TROPION-Breast01 Phase III trial
The average time of dilation lasts three to eight hours
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Subscribe To Our Newsletter & Stay Updated
